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Understanding the resistance of glioma cells to chemotherapy has been an enormous challenge. In
particular, mechanisms by which tumor cells acquire resistance to chemotherapy under hypoxic
conditions are not fully understood. In this study, we have found that miR-497 is overexpressed
in glioma and that hypoxia can induce the expression of miR-497 at the transcriptional level by
binding with the hypoxia response element in the promoter. Ectopic overexpression of miR-497 pro-
motes chemotherapy resistance in glioma cells by targeting PDCD4, a tumor suppressor that is
involved in apoptosis. In contrast, the inhibition of miR-497 enhances apoptosis and increases the
sensitivity of glioma cells to TMZ. These results suggest that miR-497 is a potential molecular target
for glioma therapy.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypoxia is a common characteristic of rapidly growing tumors
[1]. Hypoxic conditions induce many different types of physiolog-
ical or pathophysiological responses, including high-altitude adap-
tation, stroke, wound healing, myocardial infarction, and cancer
[2]. These changes are carefully controlled by a large number of
hypoxia-inducible genes [2]. Among these genes, hypoxia-induc-
ible factor 1a (HIF1a) is the key transcription factor induced by
hypoxia, increasing the expression of many genes that are involved
in metastasis, tumor recurrence, and angiogenesis [3–5]. Hypoxia
also promotes tumor cell resistance to apoptosis [6]; however,
the detailed mechanism is not fully understood.microRNAs are
small, non-coding, single-stranded RNAs that are 20–23 nucleo-
tides in length and that suppress gene expression in a sequence-
speciﬁc manner [7]. The seed region containing two to eight bases
in the 50 portion of the miRNA sequence is important for target
mRNA recognition. miRNAs suppress gene expression via comple-
mentarity between the miRNA seed region and the 30 untranslated
region (UTR) of the target mRNA [7]. Inside the primary tumor, the
rapid growth of cancer cells frequently outgrows its blood supply,
resulting in many tumors in regions where the oxygen concentra-
tion is signiﬁcantly lower than in normal tissue. To survive in hyp-
oxic conditions, cancer cells have altered their intrinsic gene
expression patterns to inhibit apoptosis. Recent studies haveshown that hypoxia induces the expression of a large number of
miRNAs, termed ‘‘hypoxamirs’’ and that these miRNAs regulate cell
proliferation, apoptosis, and metastasis [8].
Aberrant expression of miR-497 has been implicated in numer-
ous types of cancers and appears to be signiﬁcantly associated with
the clinical outcome of human cancer patients. For example, the
methylation status of CpG islands upstream of the miR-497 gene
has been shown to downregulate miR-497 [9]. Forced overexpres-
sion of miR-497 has been shown to inhibit breast cancer cell
growth and invasion [9]. In hepatocellular carcinoma, miR-497
was reported to be a tumor suppressive miRNA, showing growth-
suppressive activities by targeting CDK6, CCNE1, CDC25A, and
CDK4 [10].
However, it has not been clear whether miR-497 is involved in
the drug resistance of glioma. In this study, we found that miR-497
is overexpressed in human glioma cancer tissue and that hypoxia
can induce the expression of miR-497 at the transcriptional level
by binding with the hypoxia response element in the promoter.
Ectopic expression of miR-497 promotes chemotherapy resistance
in glioma cells by targeting PDCD4, suggesting that miR-497 is a
potential molecular target for sensitizing treatment.
2. Materials and methods
2.1. Cell culture and reagents
Glioma cells U87 and U251 and HEK293T cells were purchased
from American Type Culture Collection (Manassas, VA, USA). All
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(fetal bovine serum) and antibiotics. SYBR Green PCR master mix
and TaqMan microRNA reverse transcription kit were purchased
from ABI (Foster, CA, USA). Antibodies against PDCD4, PARP, and
cleaved PARP were purchased from Cell Signaling Technology (Bos-
ton, MA, USA). Temozolomide was purchased from Sigma. The
Dual-Luciferase Reporter Assay kit was purchased from Promega
(Madison, WI, USA).
2.2. Plasmids and constructs
To construct the pmirGLO-PDCD4-30UTR-WT plasmid, a frag-
ment of the wild-type 30UTR of human PDCD4 mRNA (GenBank
accession number: NM_014456.4) containing the putative
miR-497 binding sequence was ampliﬁed and cloned into the
SacI and XhoI sites of the pmirGLO-control vector (Promega).
pmirGLO-PDCD4-30UTR-MUT, which carried mutations in the
sequence complementary to the seed region of miR-497, was
generated based on the pmirGLO-PDCD4-30UTR-WT plasmid by
site-speciﬁc mutagenesis using the following primers: forward pri-
mer: 5-aagttaaccaggtaaaaccccatgttgggtccaggt-3; reverse primer:
5-acctggacccaacatggggtt-3.
2.3. Transfections
All transfection assays were performed using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. The miR-497 inhibitor, negative controls (scram-
bles), and miR-497 mimics were purchased from GenePharma
(Shanghai, China). The miR-497 inhibitor and mimics were used
at a ﬁnal concentration of 50 nM.
2.4. Luciferase reporter assay
For the luciferase reporter assay, 293T cells were seeded in a 24-
well plate and were grown to 80–90% conﬂuence. To detect the
interaction between miR-497 and PDCD4 30UTR, cells were
cotransfected with 50 nM of either scramble or miR-497 mimics
and 40 ng of either pmirGLO-PDCD4-30UTR-WT or pmirGLO-
PDCD4-30UTR-MUT using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocol. To detect whether the putative
HRE in the miR-497 promoter was functional, 293T cells were
transfected with wtHRE1, mut1HRE1, mut2HRE1, or mut3HRE1
and cultured in 1% O2 conditions. The cells were collected 48 h
after transfection and analyzed using the Dual-Luciferase Reporter
Assay System. A plasmid constitutively expressing Renilla lucifer-
ase was cotransfected as an internal control to correct for differ-
ences in both transfection and harvesting efﬁciencies. The
transfections were performed in duplicate, and at least three inde-
pendent experiments were performed.
2.5. Western blotting
Cells were harvested in lysis buffer (10 mM, Tris–HCl pH 7.5,
150 mM NaCl, 1% Triton X-100), containing protease and phospha-
tase inhibitors (Roche Applied Science). Samples were incubated
for 15 min on ice and centrifuged 10 min at 13000 rpm at 4 C. Pro-
tein concentrations were determined using the BCA reagent of cell
lysate (40 lg) was separated by SDS–PAGE and transferred to a
PVDF membrane (Fisher Scientiﬁc). After blocking for 60 min in
TBST (10 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.05% Tween-20)
with 5% skim milk, membranes were incubated with the primary
antibody for 1 h, washed, and incubated for 30 min with horserad-
ish peroxidase-conjugated secondary antibody. The membranes
were washed and incubated with enhanced chemiluminescence
substrate (BioRad).2.6. Quantitative RT-PCR
Total RNA was isolated from cells using Trizol Reagent (Life
Technologies), and 1 lg of total RNA was reverse transcribed in a
50 ll reaction using TaqMan Reverse Transcription Reagents
(Applied Biosystems Inc.) with the stem loop primers. 2 ll of the
reverse transcribed product was added to the SYBR Green master
mix to quantify miRNA expression. The results were normalized
to RNU48.
2.7. ChIP assays
ChIP assays were performed using the ChIP Assay kit according
to the manufacturer’s instructions. Cells were crosslinked with 1%
formaldehyde for 20 min at 37 C and quenched in 0.125 M gly-
cine. The immunoprecipitated DNA from the sonicated cell lysates
was quantiﬁed using real-time PCR analysis with the SYBR Green
system. Primer sequences used are listed as follows: HRE1-
forward: 50-tcttttcaaaataggggacc-30; HRE1-reverse: 50-gggctgcag
tttaggggtat-30; HRE2-forward: 50-cctggagttgggggtgggga-30; HRE2-
reverse: 50-cctccatcagcccatccacc-30; NC-forward: 50-aataagttcaa
tttggagtt-30; NC-reverse: 50-gatacacaggaataccccac-30.
2.8. Apoptosis assay
Cells transfected with miR-497 mimics or miR-497 inhibitor
were treated with TMZ at a ﬁnal concentration of 100 lM and cul-
tured for 24 h to measure apoptosis. At the end of the incubation
period, ﬂoating as well as adherent cells were harvested by trypsin
and washed with PBS. Cells were stained with 5 ll annexin V and
60 ll 1 binding buffer for 15 min at room temperature in the
dark, and then 120 ll 1 binding buffer and 5 ll propidium iodide.
Apoptosis was measured using ﬂow cytometry.
3. Results
3.1. miR-497 is overexpressed in glioma
First, we analyzed the miRNA expression proﬁle from a previ-
ously published dataset (Gene expression omnibus accession
GSE25631) and found that miR-497 is overexpressed in glioma
(Fig. 1A) [11]. Next, we conﬁrmed the expression of miR-497 in gli-
oma. qRT-PCR analysis shows that among three matched sample
pairs, miR-497 expression is signiﬁcantly higher in clinical glioma
tissue than in adjacent normal tissue (Fig. 1B). These results show
that miR-497 is overexpressed in glioma.
3.2. Hypoxia induces the expression of miR-497 in glioma cells
Previous studies have shown that hypoxia induces miR-497
expression in retinoblastoma cells [12], but whether this occurs
in glioma cells has not been elucidated. To detect miR-497,
U251 and U87 cells were grown for 12 h in 1% oxygen, and
mature miR-497 was measured using quantitative PCR in these
two cell lines. The data show that the levels of mature miR-497
are signiﬁcantly increased in U251 and U87 cells under hypoxic
conditions (Fig. 2A and B). Because HIF1-a is a key transcription
factor that mediates the induction of many hypoxia-inducible
genes, we treated glioma cells with DMOG, a well-established
agent that induces HIF1-a [13], to examine whether HIF1-a can
upregulate miR-497 in cancer cells. The data show that DMOG
increases the level of miR-497 in U251 and U87 cells compared
with controls (Fig. 2Aand B). As expected, the protein level of
HIF1-a increases in U251 and U87 cells treated with 1% oxygen
and DMOG (Fig. 2C and D), as evaluated using Western blot
analysis. In contrast, knock down of HIF1a with shRNA under
Fig. 1. miR-497 is overexpressed in glioma. (A) miR-497 is signiﬁcantly overexpressed in glioma compared with normal brain in microRNA expression assays. (B) Real-time
PCR analysis shows that miR-497 is signiﬁcantly increased in glioma tissue compared with normal tissue.
Fig. 2. Hypoxia induces the expression of miR-497 in glioma cells. (A) Quantitative PCR analysis shows that hypoxia increases the level of mature miR-497 in U251 cells. (B)
Quantitative PCR analysis shows that hypoxia increases the level of mature miR-497 in U87 cells. (C)Western blot analysis shows that the protein level of HIF1a is increased in
U251 cells under hypoxic conditions and DMOG treatment. (D) Western blot analysis shows that the protein level of HIF1a is increased in U87 cells under hypoxic conditions
and DMOG treatment. (E) Quantitative PCR analysis shows that the miR-497 level is decreased in U87 cells treated with shRNA-HIF1a under hypoxic conditions (⁄⁄ represents
P < 0.01). (F) Western blot analysis shows that the protein level of HIF1a is decreased in U87 cells treated with shRNA-HIF1a under hypoxic conditions.
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(Fig. 2E and F).
3.3. HIF1-a induces the expression of miR-497 at the transcriptional
level
Given that HIF1-a is a well-characterized transcription factor,
we hypothesized that HIF1-a induces the expression of miR-497at the transcriptional level. To test this hypothesis, we ﬁrst exam-
ined the expression level of pri-miR-497 in cells under hypoxic
conditions and DOMG treatment. The real-time PCR data show that
both hypoxia and DOMG administration signiﬁcantly increase pri-
miR-497 levels (Fig. 3A). To further identify how HIF1-a regulates
miR-497 expression, we analyzed the 3000 bp region upstream of
pri-miR-497 and found that there are three hypoxia response
elements (Fig. 3B). To investigate whether HIF1-a binds to the
Fig. 3. HIF1a induces the expression of miR-497 at the transcriptional level. (A) Quantitative PCR analysis shows that hypoxia increases the level of pri-miR-497 in U251 and
U87 cells. (B) The putative HRE sites in the promoter of pri-miR-497, HRE: hypoxia response element. (C) qChIP analysis shows that HIF1a is signiﬁcantly enriched in HRE1,
but not in HRE2; NC represents the negative control without the HRE sequence (⁄⁄ represents P < 0.01). (D) The luciferase reporter assay shows that miR-497 HRE1
signiﬁcantly increases luciferase activity in hypoxic conditions and that mutant HRE1 inhibits the increased luciferase activity induced by hypoxia; mut1-HRE1 represents the
mutation of 50-acgtg-30 to 50-aaatg-30; mut2-HRE1 represents the mutation of 50-gcgtg-30 to 50-aaatg-30; mut3-HRE1 represents both mutations in mut1-HRE1 and mut2-
HRE1 (⁄⁄ represents P < 0.01).
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(ChIP) assays were performed. Our data show that HIF1-a binds
to HRE1 elements in the 1.5 kb region upstream of the miR-497
promoter (Fig. 3C). However, there is no signiﬁcant enrichment
in HRE2 (Fig. 3C), suggesting that HIF1-a regulates miR-497
expression at the transcriptional level. To further conﬁrm whether
the putative HRE1 in the miR-497 promoter is functional, a 200 bp
fragment encompassing the miR-497 promoter HRE1 was inserted
into the pGL3 promoter. HEK293T cells transfected with the wild-
type miR-497 promoter reporter, control reporter, mutant miR-497
promoter, or pSV-Renilla vector, were exposed to 20% O2 or 1% O2
for 12 h. The wild-type miR-497 promoter signiﬁcantly increases
Fluc activity in cells under hypoxic conditions (Fig. 3D). The muta-
tion in mut1-HRE1 (50-acgtg-30 to 50-aaatg-30) and in mut2-HRE1
(50-gcgtg-30 to 50-aaatg-30) at the core binding site, eliminating
HIF1a binding, leads to a signiﬁcant decrease in hypoxia-induced
Fluc activity, and the mutations in mut3-HRE1 (50-acgtg-30 to 50-
aaatg-30 and 50-gcgtg-30 to 50-aaatg-30) lead to a greater decrease
in Fluc activity than that observed for mut1-HRE1 or mut2-HRE1
(Fig. 3D). Taken together, these data demonstrate that HIF1a binds
to the site of HRE1 in the miR-497 promoter and directly activates
its transcription.
3.4. miR-497 increases glioma cell resistance to apoptosis
To explore the biological function of miR-497 in glioma cells,
TMZ-induced apoptosis was ﬁrst analyzed in U87 and U251 cells
transfected with miR-497 mimics. Flow cytometry analysis shows
that overexpression of miR-497 decreases the percentage of
annexin V positives in both cell lines (Fig. 4A and B), suggestingthat miR-497 overexpression suppresses TMZ-induced apoptosis.
To further conﬁrm the effects of miR-497 on apoptosis in glioma
cells, TMZ-induced apoptosis was analyzed in U87 and U251 cells
transfected with the miR-497 inhibitor, using tumor cells transfec-
ted with scramble oligomers as a control. Real-time PCR shows
that the miR-497 inhibitor signiﬁcantly decreases the level of
miR-497 (data not shown). Flow cytometry analysis shows that
TMZ signiﬁcantly increases the percentage of annexin V positive
cells in glioma cells transfected with miR-497 inhibitor (Fig. 4C
and D). Western blot analysis shows that TMZ dramatically induces
cleavage of PARP, a well-known marker of apoptosis; overexpres-
sion of miR-497 attenuates the level of cleaved PARP (Fig. 4E),
and the knockdown of miR-497 enhances the level of cleaved PARP
(Fig. 4F).
Taken together, these observations suggest that overexpression
of miR-497 protects the tumor cells from apoptosis and increases
tumor cell resistance to therapeutic chemicals.
3.5. miR-497 suppresses the expression of PDCD4, a tumor suppressor
involved in apoptosis
To dissect the mechanism by which miR-497 increases tumor
cell resistance to TMZ, the downstream targets of miR-497 were
identiﬁed using the web-based software Targetscan. PDCD4 is an
apoptosis-related protein that is potentially targeted by miR-497
based on the pairing of the seed sequence of miR-497 (Fig. 5C).
The 30UTR of PDCD4 was cloned into a dual-luciferase UTR vector,
as shown in the schematic, and the luciferase reporter assay was
performed. The results show that luciferase activity is signiﬁcantly
reduced by miR-497 in cells expressing wild-type PDCD4, but not
Fig. 4. miR-497 increases glioma cell resistance to apoptosis. (A) Flow cytometry analysis shows that miR-497 overexpression inhibits apoptosis induced by TMZ in U251
(⁄⁄ represents P < 0.01). (B) Flow cytometry analysis shows that miR-497 overexpression inhibits apoptosis induced by TMZ in U87 (⁄⁄ represents P < 0.01). (C) Flow cytometry
analysis shows that the knockdown of miR-497 increases apoptosis induced by TMZ in U251 (⁄⁄ represents P < 0.01). (D) Flow cytometry analysis shows that the knockdown
of miR-497 increases apoptosis induced by TMZ in U87 (⁄⁄ represents P < 0.01). (E) Western blot analysis shows that miR-497 overexpression decreases the cleaved PARP
induced by TMZ. (F) Western blot analysis shows that the knockdown of miR-497 increases the cleaved PARP induced by TMZ.
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level of PDCD4 was determined using Western blot analysis in
U87 and U251 cells transfected with miR-497 mimics or inhibitor.
The data show that overexpression of miR-497 dramatically
decreases the PDCD4 protein level (Fig. 5A); in contrast, the miR-
497 knockdown increases the PDCD4 protein level (Fig. 5B). Taken
together, these data indicate that miR-497 suppresses the expres-
sion of PDCD4.
To detect whether PDCD4 is required for miR-497 in regulating
apoptosis induced by TMZ, We knock down the expression of
PDCD4 in U251 cells transfected with miR-497 inhibitor and then
administrated these cells with TMZ. The results show that siRNA-
PDCD4 signiﬁcantly decreases the PDCD4 level in cells treated with
miR-497 inhibitor (Fig. 5E). As expected, the cleavage PARP induced
by TMZ is decreased in cells contransfected with miR-497 inhibitor
and siRNA-PDCD4 compared with the cells transfected with miR-
497 inhibitor (Fig. 5F). The data indicate that the role of miR-497
in regulating apoptosis induced by TMZ is mediated by PDCD4.4. Discussion
Glioblastoma is one of the most common and lethal forms of
cancer in the central nervous system. Surgical techniques, radio-
therapy, and chemotherapy are the main treatments for glioblas-
toma, but they have little effect in extending the outcome. The
difﬁculty in treating this cancer is that there are many mechanisms
of drug resistance to consider, such as decreased uptake of water-
soluble drugs, increased ability to repair DNA damage, reduced
apoptosis, altered drug metabolism, and increased energy-depen-
dent efﬂux of chemotherapeutic drugs that diminish the ability
of cytotoxic agents to kill cancer cells [14]. TMZ is the ﬁrst line che-
motherapeutic drug which is used for the treatment of glioma,
however, lower than 40% of glioma patients initially respond to
therapy and resistance develops rapidly. Elucidating the mecha-
nism under TMZ resistance in glioma is becoming more important.
Recent works have underscored the involvement of microRNAs in
cancer development, with several studies suggesting their involve-
Fig. 5. miR-497 suppresses the expression of PDCD4, a tumor suppressor involved in apoptosis. (A) Western blot analysis shows that overexpression of miR-497 inhibits the
protein level of PDCD4 in U251 and U87. (B) Western blot analysis shows that the knockdown of miR-497 increases the protein level of PDCD4 in U251 and U87. (C) The
sequences in the 30UTR of PDCD4 were predicted to bind to miR-497. The red nucleotides were mutated to their complementary nucleotides. (D) The luciferase reporter assay
shows that miR-497 represses luciferase activity in the wild-type UTR, but does not repress activity in the mutant UTR (⁄⁄ represents P < 0.01). (E) siRNA-PDCD4 signiﬁcantly
decreased the protein level of PDCD4 in cells transfected with miR-497 inhibitor. (F) Knock down of PDCD4 blocked the increased cleaved PARP induced by miR-497 inhibitor
under TMZ treatment.
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the emerging knowledge of miRNAs in the development of new
human therapeutic applications for overcoming anticancer drug
resistance.
Previous reports show that miR-497 is downregulated in hepa-
tocellular carcinomas and breast cancers, functioning as a tumor
suppressive miRNA [10]. However, our experimental data, along
with our analysis of a published dataset, demonstrate that miR-
497 is overexpressed in glioma. Hypoxia is a common microenvi-
ronment for all kinds of cancer. Previous studies have shown that
hypoxia induces miR-497 expression in retinoblastoma cells. We
show that hypoxia can induce the expression of miR-497 in glioma
cells. The PHD enzyme inhibitor DMOG also increases miR-497
expression in glioma cells, suggesting that HIF1a may regulate
miR-497 expression. Chromatin immunoprecipitation assay con-
ﬁrmed that HIF1a binds the conserved binding sequences in the
HRE1 (Fig. 3B) at the promoter of pri-miR-497, and thus regulates
the expression of miR-497 at transcriptional level. We are the ﬁrst
to show how hypoxia induces the miR-497 expression in glioma
cells.
Our data demonstrated that hypoxia-induced miR-497
enhanced glioma cell resistance to TMZ by targeting PDCD4.
U251 cells and U87 cells overexpressing miR-497 were more resis-
tant to TMZ treatment in vitro, as compared to the control cells. In
contrast, the inhibition of miR-497 enhanced apoptosis and
increased the sensitivity of glioma cells to TMZ treatment. Knockdown of PDCD4 level in U251 cells transfected with miR-497 inhib-
itor could block the increased cleaved PARP induced by miR-497
inhibitor under TMZ treatment. The data indicate that PDCD4 is
required for the role of miR-497 involved in drug resistance. There
observations show that miR-497 might be a molecular target for
TMZ sensitization in glioma.
In conclusion, our results demonstrate that miR-497 is signiﬁ-
cantly induced by hypoxia and an important regulator of TMZ
resistance by targeting PDCD4. The ﬁnding that miR-497 is a pre-
dictor of response to TMZ in glioma cells underlies the importance
of miR-497. Our results suggest that miR-497 represents an poten-
tial target for drug therapy via blocking miR-497 with antagomiRs
in glioma tumors.
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